Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00720083 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Phase 2 study, sponsored by Radiation Therapy Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT00720083 is a Phase 2 study that was terminated before completion, run by Radiation Therapy Oncology Group. The registered enrollment target is 34 participants.
The verdict
NCT00720083, a Phase 2 study, was terminated before completion, sponsored by Radiation Therapy Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving chemotherapy together with radiation therapy is more effective with or without vandetanib in treating patients with head and neck cancer. PURPOSE: This randomized phase II trial is studying giving chemotherapy together with radiation therapy to see how well it works compared with giving chemotherapy and radiation therapy together with vandetanib in treating patients with high-risk stage III or stage IV head and neck cancer.
Interventions
- DRUG cisplatin
- RADIATION radiation therapy
- DRUG vandetanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00720083
The ClinicalTrials.gov registry entry for NCT00720083 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00720083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00720083 about?
NCT00720083 is a clinical study titled "Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer". RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Vandetanib may stop the growth of tumor cells by blocking ...
What is the current status of trial NCT00720083?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2008-11. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00720083?
The interventions under investigation include: cisplatin (DRUG), radiation therapy (RADIATION), vandetanib (DRUG).
Who is sponsoring clinical trial NCT00720083?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.